The presence of cancer cells displaying apoptosis resistance due to insufficient activation of Bax/Bak in vivo presents a formidable therapeutic challenge, as a majority of cancer drugs rely on Bax/Bak-dependent apoptosis (44). Here, BAK1 is linked to cancer.